[go: up one dir, main page]

BRPI1009606A2 - método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição - Google Patents

método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição

Info

Publication number
BRPI1009606A2
BRPI1009606A2 BRPI1009606A BRPI1009606A BRPI1009606A2 BR PI1009606 A2 BRPI1009606 A2 BR PI1009606A2 BR PI1009606 A BRPI1009606 A BR PI1009606A BR PI1009606 A BRPI1009606 A BR PI1009606A BR PI1009606 A2 BRPI1009606 A2 BR PI1009606A2
Authority
BR
Brazil
Prior art keywords
multiple sclerosis
treating
microparticle
symptoms
linked
Prior art date
Application number
BRPI1009606A
Other languages
English (en)
Inventor
Frank B Gelder
Gillian Alison Webster
Original Assignee
Innate Immunotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Immunotherapeutics Ltd filed Critical Innate Immunotherapeutics Ltd
Publication of BRPI1009606A2 publication Critical patent/BRPI1009606A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Photographic Developing Apparatuses (AREA)
BRPI1009606A 2009-06-16 2010-01-16 método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição BRPI1009606A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ577731A NZ577731A (en) 2009-06-16 2009-06-16 Compositions and methods for treatment of multiple sclerosis
PCT/NZ2010/000112 WO2010147484A1 (en) 2009-06-16 2010-06-16 Compositions and methods for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
BRPI1009606A2 true BRPI1009606A2 (pt) 2016-10-11

Family

ID=42646236

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009606A BRPI1009606A2 (pt) 2009-06-16 2010-01-16 método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição

Country Status (20)

Country Link
US (1) US8389479B2 (pt)
EP (1) EP2442832B1 (pt)
JP (1) JP5646617B2 (pt)
CN (1) CN102458476B (pt)
AU (1) AU2010260585B2 (pt)
BR (1) BRPI1009606A2 (pt)
CA (1) CA2688766C (pt)
CY (1) CY1115714T1 (pt)
DK (1) DK2442832T3 (pt)
ES (1) ES2521565T3 (pt)
HR (1) HRP20141035T1 (pt)
IL (1) IL216993A (pt)
IN (1) IN2012DN00167A (pt)
MX (1) MX2011013661A (pt)
NZ (1) NZ577731A (pt)
PL (1) PL2442832T3 (pt)
PT (1) PT2442832E (pt)
SI (1) SI2442832T1 (pt)
SM (1) SMT201400165B (pt)
WO (1) WO2010147484A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0906312A2 (pt) * 2008-04-01 2016-07-05 Innate Therapeutics Ltd "uso de micropartícula de dpm/dna para a fabricação de composto, composição e vacina"
US20130337470A1 (en) 2010-10-25 2013-12-19 Biogen Idec Ma Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS
UY35790A (es) * 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
KR20170041116A (ko) * 2015-10-06 2017-04-14 이네이트 이뮤노테라퓨틱스 리미티드 신경계의 보호 및/또는 복구용 조성물 및 방법
WO2017059486A1 (en) * 2015-10-06 2017-04-13 Innate Immunotherapeutics Limited Compositions and methods for the treatment of epilepsy
WO2017070731A1 (en) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions and methods for the treatment of alzheimer's disease
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
MX2019010174A (es) 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
WO2019218079A1 (en) * 2018-05-18 2019-11-21 Universite Laval Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease
WO2020010221A1 (en) * 2018-07-03 2020-01-09 University Of Florida Research Foundation, Inc. Microparticle systems and their use for the treatment of multiple sclerosis
WO2021260556A1 (en) * 2020-06-22 2021-12-30 Otivio As Methods for treating spasticity using anti-spasmodic compositions and negative pressure therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043347A (en) * 1996-10-10 2000-03-28 Probe International Inc. Compositions and methods for treating viral infections
CN101010098A (zh) * 2004-07-01 2007-08-01 哥本哈根大学 通过对钩端螺旋体感染的治疗进行多发性硬化症治疗和预防的方法
WO2008070564A1 (en) 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Uses of muramyl dipeptide (mdp) for treating inflammation
JP2008251608A (ja) 2007-03-29 2008-10-16 Casio Comput Co Ltd 半導体装置およびその製造方法
WO2008150181A1 (en) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treating anthrax exposure associated conditions
WO2008150182A1 (en) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treatment of anthrax

Also Published As

Publication number Publication date
EP2442832B1 (en) 2014-08-06
NZ577731A (en) 2010-08-27
CY1115714T1 (el) 2017-01-25
EP2442832A1 (en) 2012-04-25
CA2688766A1 (en) 2010-12-16
IN2012DN00167A (pt) 2015-04-17
IL216993A (en) 2016-03-31
WO2010147484A8 (en) 2012-07-19
EP2442832A4 (en) 2013-07-03
CA2688766C (en) 2015-06-30
MX2011013661A (es) 2012-05-22
PL2442832T3 (pl) 2015-01-30
CN102458476A (zh) 2012-05-16
SI2442832T1 (sl) 2014-12-31
PT2442832E (pt) 2014-11-11
CN102458476B (zh) 2014-08-20
AU2010260585A1 (en) 2012-01-19
JP5646617B2 (ja) 2014-12-24
AU2010260585A8 (en) 2012-06-14
US8389479B2 (en) 2013-03-05
AU2010260585B2 (en) 2013-02-21
IL216993A0 (en) 2012-02-29
HK1167101A1 (en) 2013-02-01
DK2442832T3 (da) 2014-11-10
WO2010147484A1 (en) 2010-12-23
ES2521565T3 (es) 2014-11-12
SMT201400165B (it) 2015-01-15
HRP20141035T1 (hr) 2014-12-19
US20100317589A1 (en) 2010-12-16
JP2012530132A (ja) 2012-11-29

Similar Documents

Publication Publication Date Title
BRPI1009606A2 (pt) método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição
BRPI1014824A2 (pt) composição farmacêutica em forma de dose unitária e método de tratamento, prevenção ou redução da ocorrência de uma condição em um indivíduo
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
BRPI0815283A2 (pt) Equipamento para o tratamento da biomassa, método para o tratamento da biomassa, biomassa tratada e hidrolisado
BRPI1008974A2 (pt) composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
BRPI0920326A2 (pt) composição e método para tratamento da síndrome do olho ressecado
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0815387A2 (pt) composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BRPI0810806A2 (pt) Método para tratar uma lesão cutânea em um indivíduo
BRPI0818732A2 (pt) Composições de análogo de prostaglandina e métodos para tratar condições relacionadas epiteliais.
BRPI1004899A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac
IL218257A (en) A solid pharmaceutical preparation containing sglt-2 inhibitor and metformin and this drug for the treatment of metabolic disorders
BRPI0922301A2 (pt) combinações de inibidor de hsp90
BR112013026341A2 (pt) composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
BRPI0716210A2 (pt) Métodos, composições e aparelhos para tratar feridas com pressões diferentes da atmosférica
HUE054298T2 (hu) Készítmények és módszerek stroke kezelésére egy konkomittáns sztatin terápián tartott alanyban
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI0820967A2 (pt) Uso de uma composição, composição farmacêutica e método para tratamento, melhora ou profilaxia dos sintomas de uma doença inflamatória
BRPI1000030A2 (pt) métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição.
BRPI0919759A2 (pt) polipeptídeos para tratamento e prevenção de adesões
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
BRPI0916102A2 (pt) "método para a prevenção da hérnia paraestomal, método para preparar uma hérnia paraestomal e dispositivo para preparar ou reduzir a incidência da hérnia paraestomal"
HUP0700369D0 (en) Pharmaceutical compositions and method for treating schizofrenia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]